Eppendorf SE has awarded Dr. Varun Venkataramani the 2025 Eppendorf Award for Young European Investigators.

Phylloceuticals has produced its first plant-based PD-1 inhibitor monoclonal antibody only 12 weeks after launching operations in Rapid City, SD.

Xcell Biosciences collaborates with Thermo Fisher to advance Treg and TIL therapies for autoimmune and solid tumor diseases.

Brenus Pharma and InSphero presented at EACR 2025 data confirming that 3D tumor spheroids are an effective model for testing STC1010 in colorectal cancer.

Watchmaker Genomics has collaborated with Revvity to automate its DNA and RNA library preparation kits for NGS workflows on the Sciclone™ G3 NGSx platform.

Biodesix, in partnership with Bio-Rad, contributed to the ctMoniTR Project, which demonstrated that changes in circulating tumor DNA (ctDNA) can predict cancer treatment outcomes.

A new study highlights IsoPSA’s ability to identify low-risk prostate cancer patients who can avoid unnecessary interventions. The test also helps monitor high-risk patients more closely.

ProBioGen’s GlymaxX technology supports the FDA-approved Ziihera® antibody for HER2-positive biliary tract cancer, advancing targeted therapies.

Seer, Inc. (Nasdaq: SEER), announced that the company will showcase new findings at the 21st Annual US Human Proteome Organization (HUPO) Conference in Philadelphia, PA, from February 22-26, 2025.

Dovetail Genomics, announces the availability of its early access services for FFPE (Formalin-Fixed Paraffin-Embedded) sample analysis, offering new capabilities for detecting structural variants and profiling RNA in oncology research.